Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adalimumab (Humira)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    265 result(s) found for: Adalimumab (Humira). Displaying page 7 of 14.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2010-023692-26 Sponsor Protocol Number: D4300C00004 Start Date*: 2011-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab M...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001746-33 Sponsor Protocol Number: M14-115 Start Date*: 2014-10-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Croh...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) SK (Completed) NL (Completed) ES (Completed) DK (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-005291-32 Sponsor Protocol Number: M05-769 Start Date*: 2006-07-20
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo − Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects with...
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057035 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) SE (Completed) AT (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000612-14 Sponsor Protocol Number: 1297.4 Start Date*: 2017-01-18
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: BI 695501 versus Humira® in patients with active Crohn’s disease: a randomized, double-blind, multicenter, parallel group, exploratory trial comparing efficacy, endoscopic improvement, safety, and ...
    Medical condition: Moderately to severely active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003564-57 Sponsor Protocol Number: Adalimumab1- 2006 Start Date*: 2006-11-02
    Sponsor Name:Kuopio University Hospital
    Full Title: Adalimumab (anti TNF alfa) in the management of acute lumbar disc prolapses -a one year, randomized, placebo controlled, double blind, single center trial
    Medical condition: Patients with acute or subacute (no more than 2 months) clinical sciatica caused by herniated disc prolapse
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036852 Prolapsed lumbar disc LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004588-11 Sponsor Protocol Number: ABR64005 Start Date*: 2019-09-10
    Sponsor Name:University Maastricht
    Full Title: Control Crohn Safe Trial: Long term efficacy and safety of periodic treatment with adalimumab versus standard step-care for newly diagnosed Crohn's disease.
    Medical condition: The chronic inflammatory bowel disease Crohn's disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000636-15 Sponsor Protocol Number: 12/201/02 Start Date*: 2015-05-27
    Sponsor Name:Bangor University
    Full Title: A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica.
    Medical condition: Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, shooting or burning quality, that approximates to the dermatomal distribution of the sciatic nerve down the poste...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004559-29 Sponsor Protocol Number: M10-447 Start Date*: 2014-11-12
    Sponsor Name:AbbVie Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004781-34 Sponsor Protocol Number: W13-984 Start Date*: 2014-04-16
    Sponsor Name:AbbVie Farmacéutica S.L.U.
    Full Title: Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000537-12 Sponsor Protocol Number: 20120263 Start Date*: 2013-09-25
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014394-41 Sponsor Protocol Number: WRAP Start Date*: 2009-10-12
    Sponsor Name:Hvidovre Hospital
    Full Title: Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and s...
    Medical condition: Reumatoid artritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002366-12 Sponsor Protocol Number: Protocolversion1.0 Start Date*: 2020-04-08
    Sponsor Name:Johns Hopkins University
    Full Title: ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE)Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10022557 Intermediate uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-004673-98 Sponsor Protocol Number: ML 20538 Start Date*: 2006-10-16
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker
    Medical condition: To investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001050-41 Sponsor Protocol Number: RP1202 Start Date*: 2015-06-12
    Sponsor Name:Robarts Clinical Trials
    Full Title: A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015099-86 Sponsor Protocol Number: LUN0809 Start Date*: 2009-12-02
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Comparison of efficacy, safety and costs of outpatient biological treatment for psoriasis in daily clinical practice.
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003392-22 Sponsor Protocol Number: PS0008 Start Date*: 2018-03-19
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety o...
    Medical condition: Moderate to severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-000720-18 Sponsor Protocol Number: CNTO1959PSO3002 Start Date*: 2015-02-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010643-14 Sponsor Protocol Number: M10-791 Start Date*: 2009-07-22
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Axial Spondyloarthritis
    Medical condition: Active axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051265 Spondyloarthropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (Prematurely Ended) CZ (Completed) ES (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001690-25 Sponsor Protocol Number: CT-P17-3.1 Start Date*: 2018-11-13
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active R...
    Medical condition: Moderate to Severe Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003668-55 Sponsor Protocol Number: A3921091 Start Date*: 2013-11-07
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. Paedi...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Completed) SK (Completed) HU (Completed) DE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 20:37:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA